Redeye provides an update on Xbrane following the Lucamzi CRL and its Q3 report. The outlook for Xbrane’s ranibizumab biosimilar has become increasingly challenging, reflected in the sharp decline in the company’s valuation. As market confidence in Ximluci has waned, Xdivane is emerging as an increasingly important component of the investment case.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/